Annual Meeting

Engelking seeks to balance research and medicine

Ken Farabaugh
Jan. 19, 2023

When he was young, Luke Engelking’s mother asked him what he wanted to be when he grew up. His answer? “’A mad scientist,’” he said.

Engelking certainly was exposed to the idea of a career in science and medicine early, as his mother pursued a second career as a physician’s assistant during his high school years. “Unfortunately, she had a number of rare autoimmune diseases and was often in and out of doctors’ offices,” Engelking said. “From then on, I always knew I wanted to go to med school. However, I wasn’t always certain that I wanted a Ph.D.”

Luke Engelking
Luke Engelking

Engelking ended up doing both. He went to medical school at the University of Texas Southwestern Medical Center, where he got his M.D.–Ph.D. in the lab of Nobel laureates Michael Brown and Joe Goldstein, best known for their discovery of the low-density lipoprotein receptor and its regulation of cholesterol metabolism. He enjoyed working with Brown and Goldstein.

“It was a very productive time,” Engelking said. “I really didn’t appreciate working under their aegis when I was doing it. … Once you’re out on your own, everything is more of a struggle.”

Engelking has embraced that struggle. After a residency at Massachusetts General Hospital and a clinical and research fellowship back at UT Southwestern, he not only began seeing patients as an attending physician but also opened his own research lab as an assistant professor in the departments of internal medicine and molecular genetics, studying the role of sterol receptor element-binding proteins in colon cancer growth and progression.

Now an associate professor, Engelking balances his time between seeing patients and conducting research. In addition, he is working to establish a clinical research program in colon cancer genetics so data on mutations of enrolled patients can be made publicly available to researchers at UT Southwestern and around the world.

“It’s my hope that we’ll be able to synergize the clinical work with the work going on in the lab,” he said. “It’s a challenge to try to get all of this work to align — I hope I’m making progress, but we’re not quite there yet.”

Identifying markers of cancer cell proliferation in the intestine

As a physician, Luke Engelking practices adult gastroenterology, focusing on patients with inherited mutations that lead to colorectal cancers as in Lynch and familial adenomatous polyposis, or FAP, syndromes.

In the Engelking lab, research focuses on the roles of lipids in intestinal epithelial cell growth. The lab uses Cre-lox and CRISPR tools to alter gene expression, RNA-seq and lipidomics to profile cell markers, and intestinal organoids from both humans and mice as model systems.

The researchers hope that discovering novel mechanisms by which sterol receptor element-binding proteins, or SREBPs, regulate tumor cell growth and proliferation will present new drug targets for the treatment of colon cancer. Recently, the lab demonstrated that selective loss of SREBP-2, which blocks cholesterol synthesis, leads to overgrowth and increased proliferation of intestinal progenitor cells.

“What I really hope to do is move toward patient-oriented studies,” Engelking said. “Perhaps we’ll find patients with FAP phenotypes but unknown genetic markers. There are any number of genetic unknowns that impact underlying cancer biology.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Ken Farabaugh

Ken Farabaugh is a former ASBMB science editor.

Related articles

From the journals: JLR
Caleigh Findley
From the journals: JLR
Carmen Morcelle
From the journals: JLR
Swarnali Roy
From the Journals: JLR
Sephra Rampersad
From the journals: JLR
Sephra Rampersad

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

Being a whole person outside of work
Hobbies

Being a whole person outside of work

Nov. 1, 2024

Creating art, community service, physical exercise, theater and music — four scientists talk about the activities that bring them joy.

‘We’re thankful for our reviewers’
Journal News

‘We’re thankful for our reviewers’

Oct. 31, 2024

Meet some of the scientists who review manuscripts for the Journal of Biological Chemistry, Journal of Lipid Research and Molecular & Cellular Proteomics.

In memoriam: Bruce Ames
In Memoriam

In memoriam: Bruce Ames

Oct. 28, 2024

He invented a cheap and easy way to assess mutagenicity that helped identify many environmental and industrial carcinogens; it became known as the Ames test.

Honors for DebBurman, Margaryan and Santiago–Frangos
Member News

Honors for DebBurman, Margaryan and Santiago–Frangos

Oct. 28, 2024

The Council on Undergraduate Research honors Shubhik DebBurman with a mentoring award. Anush Margaryan wins a Projects for Peace grant to teach refugees in Armenia. UPenn names Andrew Santiago–Frangos an endowed assistant professor.

In memoriam: William L. Smith
In Memoriam

In memoriam: William L. Smith

Oct. 21, 2024

He served as associate editor of both the Journal of Biological Chemistry and the Journal of Lipid Research and was an ASBMB member for more than 40 years.

Honors for Fleming, Garcia and Lichtenstein
Member News

Honors for Fleming, Garcia and Lichtenstein

Oct. 21, 2024

Karen Fleming elected president of Biophysical Society. The Eastern Analytical Symposium honors Ben Garcia for achievements in mass spec. Tufts University names Alice Lichtenstein a distinguished professor.